comparemela.com

Latest Breaking News On - Institutional investors weigh in on alnylam pharmaceuticals - Page 2 : comparemela.com

Needham & Company LLC Reiterates Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They currently have a $200.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 33.49% from […]

Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 12-Month Low at $143 52

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) shares hit a new 52-week low on Thursday . The company traded as low as $143.52 and last traded at $146.04, with a volume of 1235397 shares trading hands. The stock had previously closed at $164.15. Wall Street Analyst Weigh In ALNY has been the topic of […]

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Expected to Earn FY2023 Earnings of ($2 49) Per Share

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Stock analysts at Leerink Partnrs increased their FY2023 EPS estimates for Alnylam Pharmaceuticals in a research report issued on Monday, January 8th. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of ($2.49) per share for the year, up from their prior […]

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Receives $227 85 Average PT from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty research firms that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.